Genome Editing and Induced Pluripotent Stem Cell Technologies for Personalized Study of Cardiovascular Diseases
Purpose of Review
The goal of this review is to highlight the potential of induced pluripotent stem cell (iPSC)-based modeling as a tool for studying human cardiovascular diseases. We present some of the current cardiovascular disease models utilizing genome editing and patient-derived iPSCs.
The incorporation of genome-editing and iPSC technologies provides an innovative research platform, providing novel insight into human cardiovascular disease at molecular, cellular, and functional level. In addition, genome editing in diseased iPSC lines holds potential for personalized regenerative therapies.
The study of human cardiovascular disease has been revolutionized by cellular reprogramming and genome editing discoveries. These exceptional technologies provide an opportunity to generate human cell cardiovascular disease models and enable therapeutic strategy development in a dish. We anticipate these technologies to improve our understanding of cardiovascular disease pathophysiology leading to optimal treatment for heart diseases in the future.
KeywordsInduced pluripotent stem cells Cardiovascular disease Genome editing Cardiomyocytes Personalized medicine
This work was supported by the National Institutes of Health grants 5R01HL104040, 5R01HL095813, and P50GM115305 to C.C.H. and by UL1TR000445 from the National Center for Advancing Translational Sciences.
Compliance with Ethical Standards
Conflict of Interest
Young Wook Chun, Matthew D. Durbin, and Charles C. Hong declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Ostergaard GH, Hansen HN, Ottesen JL. Physiological, hematological, and clinical chemistry parameters, including conversion factors. In: Hau J, Schapiro SJ, editors. Handbook of laboratory animal science, vol. 1. 3rd ed. Boca Raton: CRC press; 2010. p. 40.Google Scholar
- 8.Camacho PF, Liu H, He Z. J. Large mammalian animal models of heart disease. J Cardiovasc Dev Dis. 2016;3(30):11.Google Scholar
- 28.Jouni M, Si-Tayeb K, Es-Salah-Lamoureux Z, Latypova X, Champon B, Caillaud A, et al. Toward personalized medicine: using cardiomyocytes differentiated from urine-derived pluripotent stem cells to recapitulate electrophysiological characteristics of type 2 long QT syndrome. J Am Heart Assoc. 2015;4(9):e002159.PubMedPubMedCentralGoogle Scholar
- 49.•• Kim YB, Komor AC, Levy JM, Packer MS, Zhao KT, Liu DR. Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. Nature Biotechnol. 2017;35(4):371–6. This study reported an important technical advance that substantially increased the efficiency and precision of genome editing. CrossRefGoogle Scholar
- 51.Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet. 2001;10(11):1215–20.CrossRefPubMedGoogle Scholar
- 53.Ben Jehuda R, Eisen B, Shemer Y, Mekies LN, Szantai A, Reiter I, et al. CRISPR correction of the PRKAG2 gene mutation in a patient’s induced pluripotent stem cell-derived cardiomyocytes eliminates electrophysiological and structural abnormalities. Heart Rhythm. 2017;15(2):267–76.CrossRefPubMedGoogle Scholar
- 54.• Granata A, Serrano F, Bernard WG, McNamara M, Low L, Sastry P, et al. An iPSC-derived vascular model of Marfan syndrome identifies key mediators of smooth muscle cell death. Nat Genet. 2017;49(1):97–109. Using iPSC-based cell models and genome editing, this study identified key mediators of Marfan syndrome pathophysiology as well as potential therapeutic strategy. CrossRefPubMedGoogle Scholar
- 58.• Feaster TK, Cadar AG, Wang L, Williams CH, Chun YW, Hempel JE, et al. Matrigel mattress: a method for the generation of single contracting human-induced pluripotent stem cell-derived cardiomyocytes. Circulation Res. 2015;117(12):995–1000. This study describes a relatively simple method to rapidly promote human iPSC-CM maturation for functional evaluation of patient-specific cardiomyocytes. PubMedPubMedCentralGoogle Scholar